Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical pharmacokinetics of sulphasalazine.

Clinical pharmacokinetics - 1 Jan 2000

Das K M, Dubin R

Abstract excerpt

Sulphasalazine consists of 5-aminosalicylic acid and sulphapyridine both linked together by an azo bond. Sulphasalazine is clearly useful in long-term management of ulcerative colitis and may be useful in Crohn's disease. The absorption, metabolism and excretion of sulphasalazine is similar in volunteers and patients with ulcerative colitis or Crohn's disease. Sulphasalazine serves as a vehicle to deliver its...

Topics

Acetylation
Animals
Anti-Bacterial Agents
Binding, Competitive
Calcium
Drug Interactions
Folic Acid
Humans
Intestinal Absorption
Iron
Kinetics
Phenobarbital

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Phenotype

Protein Binding

Sulfasalazine

Time Factors

Source

Identifiers

PMID: 15752
DOI: 10.2165/00003088-197601060-00002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-15752-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical pharmacokinetics of sulphasalazine.PMID 15752Read ↗

Formation and elimination of sulphamethoxazole hydroxylamine after oral administration of sulphamethoxazole.Semantic proximity Read ↗

Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.Semantic proximity Read ↗

Pharmacokinetics, acetylation-deacetylation, renal clearance, and protein binding of sulphamerazine, N4-acetylsulphamerazine, and N4-trideuteroacetylsulphamerazine in 'fast' and 'slow' acetylators.Semantic proximity Read ↗

N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.Semantic proximity Read ↗

N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis.Semantic proximity Read ↗

Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.Semantic proximity Read ↗

Pharmacokinetics, metabolism and renal excretion of sulfatroxazole and its 5-hydroxy- and N4-acetyl-metabolites in man.Semantic proximity Read ↗

Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics.Semantic proximity Read ↗

Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis.Semantic proximity Read ↗

Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.Semantic proximity Read ↗

N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.Semantic proximity Read ↗

N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.